Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 2
2001 1
2002 3
2003 1
2004 2
2005 5
2006 6
2007 3
2008 3
2009 4
2010 1
2012 2
2013 1
2014 4
2015 5
2016 7
2018 1
2019 5
2020 6
2021 2
2022 4
2023 8
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O; EUSTAR collaborators. Hoffmann-Vold AM, et al. Ann Rheum Dis. 2021 Feb;80(2):219-227. doi: 10.1136/annrheumdis-2020-217455. Epub 2020 Sep 28. Ann Rheum Dis. 2021. PMID: 32988845 Free PMC article.
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, Damjanov N, Rednic S, Ribi C, Bancel DF, Hoffmann-Vold AM, Gabrielli A, Distler O, Khanna D, Allanore Y; EUSTAR collaborators. Lescoat A, et al. JAMA Dermatol. 2023 Aug 1;159(8):837-847. doi: 10.1001/jamadermatol.2023.1729. JAMA Dermatol. 2023. PMID: 37378994 Free PMC article.
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Among authors: litinsky i. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.
Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM, Siegert E, Henes J, Zanatta E, Riccieri V, Truchetet ME, Oksel F, Li M, Kucharz EJ, Eyerich K, Del Galdo F, Vonk MC, Vold AH, Gabrielli A, Distler O; EUSTAR collaborators. Wyss A, et al. Arthritis Res Ther. 2024 Oct 31;26(1):187. doi: 10.1186/s13075-024-03418-2. Arthritis Res Ther. 2024. PMID: 39482761 Free PMC article.
Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database.
Mongin D, Matucci-Cerinic M, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR Collaborators. Mongin D, et al. Arthritis Care Res (Hoboken). 2025 May;77(5):649-657. doi: 10.1002/acr.25469. Epub 2025 Jan 14. Arthritis Care Res (Hoboken). 2025. PMID: 39542851 Free article. Clinical Trial.
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.
Elhai M, Sritharan N, Boubaya M, Balbir-Gurman A, Siegert E, Hachulla E, de Vries-Bouwstra J, Riemekasten G, Distler JHW, Rosato E, Del Galdo F, Mendoza FA, Furst DE, de la Puente C, Hoffmann-Vold AM, Gabrielli A, Distler O, Bloch-Queyrat C, Allanore Y; EUSTAR collaborators. Elhai M, et al. Lancet Rheumatol. 2022 Nov;4(11):e785-e794. doi: 10.1016/S2665-9913(22)00217-X. Lancet Rheumatol. 2022. PMID: 38265945
The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.
Bellando-Randone S, Wilhalme H, Bruni C, Czirjak L, Distler O, Allanore Y, Cuomo G, Denton C, Del Galdo F, Gheorghiu AM, Riccieri V, Walker U, Truchetet ME, Vonk MC, Foeldvari I, Matucci-Cerinic M, Furst DE; and the EUSTAR collaborators. Bellando-Randone S, et al. Arthritis Res Ther. 2025 Mar 27;27(1):66. doi: 10.1186/s13075-025-03476-0. Arthritis Res Ther. 2025. PMID: 40148996 Free PMC article.
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
Zanatta E, Huscher D, Ortolan A, Avouac J, Airò P, Balbir-Gurman A, Siegert E, Matucci Cerinic M, Cozzi F, Riemekasten G, Hoffmann-Vold AM, Distler O, Gabrielli A, Heitmann S, Hunzelmann N, Montecucco C, Morovic-Vergles J, Ribi C, Doria A, Allanore Y; EUSTAR collaborators. Zanatta E, et al. Rheumatology (Oxford). 2022 Nov 28;61(12):4786-4796. doi: 10.1093/rheumatology/keac188. Rheumatology (Oxford). 2022. PMID: 35348643
68 results